承葛生物完成过亿元融资，聚焦微生态医疗领域

Core Insights - Shanghai Chengge Biotechnology Co., Ltd. has successfully completed a strategic investment round led by Suzhou Jinhui Capital, focusing on the micro-ecological medical field [1][3] - The company has developed the world's first integrated platform for Precision Microbiota Transplantation Therapy (PMTT), which includes a comprehensive solution for deep microbiota analysis, precise matching, standardized preparation, and intelligent delivery [1][3] Company Overview - Chengge Biotechnology, founded in 2016, is a national high-tech enterprise providing comprehensive solutions for precise microbiota transplantation, integrating R&D, manufacturing, sales, and services [3][4] - The company has established itself as a leading player in the industry, with a focus on human micro-ecological transplantation and various related fields, including micro-ecological health, diagnosis, treatment, and data mining [4] Technological Advancements - The PMTT platform includes a "precision screening" sample library, an "intelligent matching" technology platform, and a "standardized production" center that adheres to advanced GMP standards, ensuring safety and efficacy [1][3] - The core product, "liquid live bacteria enteric-coated capsules," has demonstrated significant clinical value [1] Industry Potential - Micro-ecological intervention is viewed as a crucial development direction in future medicine, with Chengge Biotechnology positioned as a pioneer in this field [3] - The company aims to address major clinical needs and promote the industrialization of micro-ecological medicine, benefiting a broader patient population [3]